Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1975 1
1976 3
1977 3
1978 3
1979 5
1980 1
1981 6
1982 1
1983 4
1984 10
1985 6
1986 9
1987 8
1988 9
1989 12
1990 16
1991 12
1992 10
1993 8
1994 21
1995 20
1996 14
1997 17
1998 23
1999 30
2000 29
2001 20
2002 29
2003 28
2004 28
2005 32
2006 62
2007 66
2008 67
2009 78
2010 55
2011 86
2012 104
2013 99
2014 122
2015 144
2016 128
2017 131
2018 99
2019 99
2020 122
2021 126
2022 94
2023 98
2024 39

Text availability

Article attribute

Article type

Publication date

Search Results

1,941 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Thrombocythemia 2"
Page 1
Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management.
Tefferi A, Barbui T. Tefferi A, et al. Am J Hematol. 2020 Dec;95(12):1599-1613. doi: 10.1002/ajh.26008. Epub 2020 Oct 23. Am J Hematol. 2020. PMID: 32974939 Free article. Review.
DISEASE OVERVIEW: Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms (MPN) respectively characterized by clonal erythrocytosis and thrombocytosis; other disease features include leukocytosis, splenomegaly, thrombosis, bleeding …
DISEASE OVERVIEW: Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms (MPN) respectively chara …
Essential thrombocythemia: challenges in clinical practice and future prospects.
Godfrey AL, Green AC, Harrison CN. Godfrey AL, et al. Blood. 2023 Apr 20;141(16):1943-1953. doi: 10.1182/blood.2022017625. Blood. 2023. PMID: 36379024 Free article. Review.
Essential thrombocythemia (ET) was first described in 1934, and subsequently, progress has been made in better understanding the molecular pathogenesis and which patients may have greatest risk of progression or vascular events. ...
Essential thrombocythemia (ET) was first described in 1934, and subsequently, progress has been made in better understanding the mole …
Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management.
Tefferi A, Vannucchi AM, Barbui T. Tefferi A, et al. Am J Hematol. 2024 Apr;99(4):697-718. doi: 10.1002/ajh.27216. Epub 2024 Jan 25. Am J Hematol. 2024. PMID: 38269572 Review.
OVERVIEW: Essential thrombocythemia is a Janus kinase 2 (JAK2) mutation-prevalent myeloproliferative neoplasm characterized by clonal thrombocytosis; clinical course is often indolent but might be interrupted by thrombotic or hemorrhagic complications, microc …
OVERVIEW: Essential thrombocythemia is a Janus kinase 2 (JAK2) mutation-prevalent myeloproliferative neoplasm characterized by …
Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera.
Tefferi A, Guglielmelli P, Lasho TL, Coltro G, Finke CM, Loscocco GG, Sordi B, Szuber N, Rotunno G, Pacilli A, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Vannucchi AM. Tefferi A, et al. Br J Haematol. 2020 Apr;189(2):291-302. doi: 10.1111/bjh.16380. Epub 2020 Jan 16. Br J Haematol. 2020. PMID: 31945802 Free article.
Survival prediction in essential thrombocythaemia (ET) and polycythaemia vera (PV) is currently based on clinically-derived variables; we examined the possibility of integrating genetic information for predicting survival. ...Multivariable analysis identified spliceosome m …
Survival prediction in essential thrombocythaemia (ET) and polycythaemia vera (PV) is currently based on clinically-derived variables …
Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
Tefferi A, Barbui T. Tefferi A, et al. Am J Hematol. 2019 Jan;94(1):133-143. doi: 10.1002/ajh.25303. Epub 2018 Nov 9. Am J Hematol. 2019. PMID: 30281843 Free article.
Disease Overview: Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms respectively characterized by erythrocytosis and thrombocytosis; other disease features include leukocytosis, splenomegaly, thrombosis, bleeding, microcircul …
Disease Overview: Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms respectively characteriz …
Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.
Harrison CN, Mead AJ, Panchal A, Fox S, Yap C, Gbandi E, Houlton A, Alimam S, Ewing J, Wood M, Chen F, Coppell J, Panoskaltsis N, Knapper S, Ali S, Hamblin A, Scherber R, Dueck AC, Cross NCP, Mesa R, McMullin MF. Harrison CN, et al. Blood. 2017 Oct 26;130(17):1889-1897. doi: 10.1182/blood-2017-05-785790. Epub 2017 Aug 9. Blood. 2017. PMID: 29074595 Free PMC article. Clinical Trial.
Treatments for high-risk essential thrombocythemia (ET) address thrombocytosis, disease-related symptoms, as well as risks of thrombosis, hemorrhage, transformation to myelofibrosis, and leukemia. Patients resistant/intolerant to hydroxycarbamide (HC) have a poor ou …
Treatments for high-risk essential thrombocythemia (ET) address thrombocytosis, disease-related symptoms, as well as risks of …
Essential thrombocythemia and pregnancy.
Valera MC, Parant O, Vayssiere C, Arnal JF, Payrastre B. Valera MC, et al. Eur J Obstet Gynecol Reprod Biol. 2011 Oct;158(2):141-7. doi: 10.1016/j.ejogrb.2011.04.040. Epub 2011 Jun 2. Eur J Obstet Gynecol Reprod Biol. 2011. PMID: 21640467 Review.
Essential thrombocythaemia (ET) is an acquired myeloproliferative neoplasm, characterised by persistent thrombocytosis and a tendency for either thrombosis or haemorrhage. ...
Essential thrombocythaemia (ET) is an acquired myeloproliferative neoplasm, characterised by persistent thrombocytosis and a t …
Polycythemia vera and essential thrombocythemia: algorithmic approach.
Vannucchi AM, Guglielmelli P, Tefferi A. Vannucchi AM, et al. Curr Opin Hematol. 2018 Mar;25(2):112-119. doi: 10.1097/MOH.0000000000000402. Curr Opin Hematol. 2018. PMID: 29194068 Review.
PURPOSE OF REVIEW: To describe an algorithm-based approach, whenever available, to the diagnosis, the risk stratification criteria informing therapy and the current management of polycythemia vera and essential thrombocythemia. RECENT FINDINGS: Description of recurrent gen …
PURPOSE OF REVIEW: To describe an algorithm-based approach, whenever available, to the diagnosis, the risk stratification criteria informing …
Essential thrombocythemia treatment algorithm 2018.
Tefferi A, Vannucchi AM, Barbui T. Tefferi A, et al. Blood Cancer J. 2018 Jan 10;8(1):2. doi: 10.1038/s41408-017-0041-8. Blood Cancer J. 2018. PMID: 29321520 Free PMC article. Review.
Current drug therapy for myeloproliferative neoplasms, including essential thrombocythemia (ET) and polycythemia vera (PV), is neither curative nor has it been shown to prolong survival. ...
Current drug therapy for myeloproliferative neoplasms, including essential thrombocythemia (ET) and polycythemia vera (PV), is neithe …
Emerging drugs for essential thrombocythemia.
Masarova L, Verstovsek S. Masarova L, et al. Expert Opin Emerg Drugs. 2019 Jun;24(2):93-105. doi: 10.1080/14728214.2019.1615437. Epub 2019 May 14. Expert Opin Emerg Drugs. 2019. PMID: 31050912 Review.
Introduction: Despite our recent progress in the understanding of essential thrombocythemia (ET) pathogenesis, the therapeutic management of this disease has remained largely unchanged in the past decades. ...The classes of agents described in this review include targeted …
Introduction: Despite our recent progress in the understanding of essential thrombocythemia (ET) pathogenesis, the therapeutic manage …
1,941 results